Johnson & Johnson (JNJ) anticipates a $400M tariff impact by 2025 due to new trade levies, mainly slapped on MedTech goods.

For the first quarter of this year, J&J’s total sales of $21.9 billion were up 4.2% over the start of 2024, when accounting ...

Barclays lowered the firm’s price target on Johnson & Johnson to $165 from $166 and keeps an Equal Weight rating on the shares following ...

US stocks drifted lower Tuesday as investors considered the latest developments on President Trump's tariffs, including a potential auto sector reprieve and a concrete step toward new ...

Johnson & Johnson is set to release first-quarter results on Tuesday before the market opens. Here is what you need to know.

Johnson & Johnson raised its 2025 sales outlook and dividend, while Q1 results topped expectations driven by strong cancer drug performance.

Shares of Johnson & Johnson and Amgen are trading lower Wednesday morning, sending the Dow Jones Industrial Average into negative territory. Supported by world-class markets data from Dow Jones ...

One big reason the Dow Jones Industrial Average slipped Tuesday had little to do with tariffs. Johnson & Johnson's stock tumbled 6.5% after a bankruptcy judge dismissed an attempt by the ...